Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms CaboPembro UC
- 20 Sep 2018 Status changed from not yet recruiting to recruiting.
- 20 Sep 2018 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.
- 20 Sep 2018 Planned primary completion date changed from 1 Aug 2023 to 1 Sep 2023.